Vevo Therapeutics and Parse Biosciences Collaboration

In a groundbreaking partnership, Vevo Therapeutics has teamed up with Parse Biosciences’ cutting-edge GigaLab to create an unprecedented dataset of 100 million single cells, aimed at enhancing AI-driven drug discovery. This innovative collaboration marks a significant leap forward for both Vevo and its Mosaic platform, allowing them to generate critical data at an extraordinary scale and speed.

Quotes from Leadership

“Our collaboration with Parse represents a pivotal moment for us,” exclaimed Johnny Yu, PhD, Chief Scientific Officer and Co-founder of Vevo. “Over the past two years, we’ve continuously refined our platform, and with the resources of the Parse GigaLab, we are now poised to accelerate the discovery of new treatments like never before.”

The Power of GigaLab

The Parse GigaLab utilizes its proprietary Evercode™ technology, ensuring the swift generation of massive single-cell datasets. Incredibly, the recent Tahoe-100 dataset created with Vevo was completed in the wet lab within merely one month. This achievement is made possible through high-quality, ultra-low-cost sequencing enabled by the innovative UG 100™ platform developed in partnership with Ultima Genomics.

Commitment to Speed and Quality

“The GigaLab showcases our commitment to delivering rapid, high-quality, and scalable data generation,” stated Alex Rosenberg, CEO and Co-founder of Parse Biosciences. “Our partnership with Vevo paves the way for groundbreaking advancements in drug development and discovery, benefiting the entire biopharma sector.”

About Parse Biosciences

Based in Seattle's dynamic South Lake Union district, Parse Biosciences is leading the charge in the life sciences industry. With over 2,000 global customers, the company’s innovative products—ranging from Evercode™ Whole Transcriptome to advanced data analysis solutions—empower researchers to conduct single-cell sequencing with unprecedented efficiency. The company has garnered significant investment of over $100 million, positioning it at the forefront of scientific research and human health advancements.

Vevo Therapeutics

Located in San Francisco, CA, Vevo Therapeutics is setting a new standard in biotechnology by employing advanced in vivo drug discovery methodologies powered by next-gen AI models. The company's Mosaic platform represents a revolutionary approach to drug development, capturing detailed in vivo data to enhance the understanding of patient responses. Vevo's ambitious goal is to establish the largest in vivo cell atlas, facilitating the identification of novel drug targets that traditional methods may overlook.

Future Prospects

With the support of esteemed investors at the intersection of life sciences and technology—including General Catalyst and Wing Venture Capital—Vevo is reshaping the future of drug discovery. As this transformative partnership unfolds, the world eagerly anticipates the innovative breakthroughs that could emerge from Vevo and Parse’s collaboration. The potential for advancements in treatment options has never been more promising, with both companies working tirelessly to push the boundaries of what is possible in drug development.